Oragenics, Inc. has appointed John Spencer as its new Chief Financial Officer, effective July 1, 2026. Mr. Spencer will receive a base salary of $200,000 and an option award valued at $25,000. The company held its Annual Meeting on June 29, 2026, where shareholders re-elected all six directors. Shareholders also approved a non-binding advisory vote on executive compensation. A significant proposal passed was the authorization for the Board of Directors to enact a reverse stock split, with ratios ranging from 1-for-2 to 1-for-50, within one year. The selection of Cherry Bekaert LLP as the independent auditors for the year ending December 31, 2026, was ratified.